News
Novartis receives approval for first malaria medicine for newborn babies and young infants
Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic)
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the ...
A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...
As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...
Investor's Business Daily on MSN3d
Stocks Generating Improved Relative Strength: Novartis ADRNovartis ADRNVS saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 69 to 76. Please watch the video at Investors.com - How To Scale Out Of Losing Stocks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback